Diagnostics
Epigenomics AG today announced the initiation of a multi-center validation and development study of its methylated cell free DNA biomarkers to aid in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.
Epigenomics AG today announced that the Centers for Medicare & Medicaid Services (CMS) have issued its official 2019 Clinical Lab Fee Schedule (CLFS) on December 14, 2018, including the final reimbursement rate of $192 for Epi proColon®, the first and only FDA-approved blood test for colorectal cancer screening.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Yet another company has launched to develop liquid biopsies. Founded and headed by Omid Farokhzad, formerly a professor at Brigham and Women’s Hospital, Seer is based in San Francisco.
QuantuMDx Group Limited and Molbio Diagnostics Private Limited have signed a memorandum of understanding (MoU) to explore opportunities for joint working in infectious disease diagnostics, with an initial focus on genotypic drug resistance testing for those infected with tuberculosis.
With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
According to consultant firm Frost & Sullivan, artificial intelligence (AI) systems will be the next big players in both global healthcare and individual gene editing. By 2021, the firm predicts that AI will be responsible for 6.7 billion dollars in revenue.
The U.S. Food and Drug Administration (FDA) has issued an approval letter for the new features and intended uses of the Planmed Verity® CBCT scanner. Planmed is very pleased to bring these exciting improvements to the U.S. market.
Many recent college graduates with science degrees wonder, “What other careers are available outside of a laboratory or research environment?” Concurrently, a large amount of mid-career and late-career professionals consider pursuing non-traditional science roles.
INTEGRA’s VIAFLO 96 electronic multi-channel pipetting system is helping biotechnology company HCS Pharma to improve the reproducibility of high content screening using its patented BIOMIMESYS® 3D cell culture technology.
PRESS RELEASES